Baseline Cardiometabolic Markers
Both diets start from matched baseline risk profiles.
- 130 mg/dL: LDL cholesterol (typical trial entry)
- 45 mg/dL: HDL cholesterol (matched cohorts)
- 105 mg/dL: Fasting glucose (prediabetic range)
- 12 months: Trial duration (standard comparison window)
Randomized trial design
Participants matched for weight, age, and baseline labs.
Why baseline matters
Identical starting points isolate true diet effects.
Tracking method
Markers reassessed at 3, 6, and 12 months.
Baseline equivalence isolates diet effects from confounding factors.
3-Month Lipid Panel Divergence
Low-carb lifts LDL faster than Mediterranean early on.
- +12%: LDL change, low-carb (3-month rise)
- -2%: LDL change, Mediterranean (3-month change)
- +4%: HDL change, low-carb (modest early gain)
- +6%: HDL change, Mediterranean (steadier early gain)
Saturated fat intake
Low-carb diets often raise saturated fat consumption.
Olive oil effect
Mediterranean olive oil favors healthier lipid particles.
Particle size nuance
Low-carb LDL particles may shift toward a benign subtype.
LDL rise on low-carb doesn't always signal higher cardiovascular risk.
Glycemic Control Comparison
Low-carb drops glucose faster in the short term.
- -18%: Glucose, low-carb 3mo (rapid short-term drop)
- -10%: Glucose, Mediterranean 3mo (gradual short-term drop)
- -0.6 pt: HbA1c, low-carb (absolute change)
- -0.3 pt: HbA1c, Mediterranean (absolute change)
Carbohydrate restriction
Fewer carbs directly lowers post-meal glucose spikes.
Insulin sensitivity
Mediterranean improves insulin sensitivity more gradually.
Durability question
Low-carb's early glucose edge often narrows by month twelve.
Short-term glucose gains don't always predict long-term diabetes outcomes.
Cardiovascular Marker Trends
Mediterranean shows stronger long-term cardiovascular outcome evidence.
- -5%: CV risk marker, low-carb (12-month composite)
- -18%: CV risk marker, Mediterranean (12-month composite)
- -30%: Major CV events (PREDIMED) (relative risk reduction)
- -20%: hs-CRP, Mediterranean (inflammation marker drop)
PREDIMED trial evidence
Landmark trial linked Mediterranean diet to fewer CV events.
Inflammation pathway
Polyphenols and omega-3s lower systemic inflammation markers.
Low-carb CV data gap
Long-term low-carb cardiovascular outcome trials remain limited.
Mediterranean diet carries the strongest hard-outcome trial evidence to date.
12-Month Comparative Outcomes
Both diets improve markers with different risk tradeoffs.
- +8%: LDL change, low-carb (12-month value)
- -6%: LDL change, Mediterranean (12-month value)
- +14%: HDL change, Mediterranean (12-month value)
- -15%: Glucose change, low-carb (12-month value)
Choosing a diet
Individual risk profile should guide diet selection.
Combining strengths
Low-carb glycemic gains plus Mediterranean lipid safety may work.
Clinical takeaway
Both diets beat standard low-fat advice in trials.
No single diet wins every cardiometabolic marker outcome.